15 research outputs found
Photoresponse of YBa2Cu3O(7-delta) granular and epitaxial superconducting thin films
The response is reported of thin films of YBa2Cu3O(7-delta) with either a very grainy or a smooth epitaxial morphology to visible radiation. SrTiO3 substrates were employed for both types of films. The grainy films were formed by sequential multi-layer electron beam evaporation while the epitaxial films were formed by laser ablation. Both films were patterned into H shaped detectors via a negative photolithographic process employing a Br/ethanol etchant. The bridge region of the H was 50 microns wide. The patterned films formed by laser ablation and sequential evaporation had critical temperatures of 74 K and 72 K respectively. The bridge was current biased and illuminated with chopped He-Ne laser radiation and the voltage developed in response to the illumination was measured. A signal was detected only above the critical temperature and the peak of the response coincided with the resistive transition for both types of films although the correspondence was less exact for the grainy film. The details of the responses and their analysis are presented
Influence of Gear Design Parameters on Gearbox Radiated Noise
Spur and helical gears were tested in the NASA gear-noise rig to compare the noise produced by different gear designs. Sound power measurements were performed under controlled conditions for a matrix of operating conditions. Sound power was computed from near-field acoustic intensity scans taken just above the top surface of the gearbox. Test gears included four spur and five helical gear designs. The gears were designed to be as nearly identical as possible except for deliberate differences in tooth geometry and contact ratio. Test results are presented as a function of the gear design and operating conditions in the form of sound power charts and as narrow-band spectra
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients
Background
Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown.
Methods
Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated d-dimer level (cohort 1), patients with an elevated d-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding.
Results
A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P=0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P=0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P=0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P=0.55).
Conclusions
Among acutely ill medical patients with an elevated d-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX ClinicalTrials.gov number, NCT01583218. opens in new tab.
The CERN Axion Solar Telescope (CAST)
A decommissioned LHC test magnets is being prepared as the CERN Axion Solar Telescope (CAST) experiment. The magnet has a field of 9.6 Tesla and length of 10 meters. It is being mounted on a platform to track the sun over +/-8(0) vertically and +/-45(0), horizontally. A sensitivity in axion-photon coupling g(agammagamma) < 5 x 10(-11)GeV(-1) can be reached for m(a) less than or equal to 10(-2) eV, and with a gas filled tube-can reach g(agammagamma) less than or equal to 10(-10)GeV(-1) for axion masses m(a) < 2eV
The CERN Axion Solar Telescope (CAST)
A decommissioned LHC test magnet is being prepared as the CERN Axion Solar Telescope (CAST) experiment. The magnet has a field of 9.6 Tesla and length of 10 meters. It is being mounted on a platform to track the sun over +/-8(0) vertically and +/-45(0), horizontally. A sensitivity in axion-photon coupling g(agammagamma) < 5 x 10(-11)GeV(-1) can be reached for m(a) less than or equal to 10(-2) eV, and with a gas filled tube-can reach g(agammagamma) less than or equal to 10(-10)GeV(-1) for axion masses m(a) < 2eV